Search

Aims: To provide real‐world data on the addition of basal insulin (BI) in people with type 2 diabetes mellitus (PWD2) suboptimally controlled with glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy. However, real‐world data on the addition of BI to GLP‐1RA therapy are limited. Materials and Methods: We used a US electronic medical record data source (IBM® Explorys®) that includes approximately 4 million PWD2 to assess the real‐world impact of adding the second‐generation BI analogue insulin glargine 300 U/mL (Gla‐300) to GLP‐1RA therapy. Insulin‐naïve PWD2 receiving GLP‐1RAs who also received Gla‐300 between March 1, 2015 and September 30, 2019 were identified; participants were required to have data for ≥12 months before, and ≥6 months after, addition of Gla‐300. Results: The mean (standard deviation [SD]) age of participants (N = 271) was 57.9 (10.8) years. Baseline glycated haemoglobin (HbA1c) was 9.16% and was significantly reduced (−0.97 [SD 1.60]%; P < 0.0001) after addition of Gla‐300; a significant increase in the proportion of PWD2 achieving HbA1c control was observed after addition of Gla‐300 (HbA1c <7.0%: 4.80% vs. 22.14%, P < 0.0001; HbA1c <8.0%: 19.56% vs. 51.29%, P < 0.0001). The incidence of overall (8.49% vs. 9.59%; P = 0.513) and inpatient/emergency department (ED)‐associated hypoglycaemia (0.37% vs. 0.74%; P = 1.000), as well as overall (0.33 vs. 0.46 per person per year [PPPY]; P = 0.170) and inpatient/ED‐associated hypoglycaemia events (0.01 vs. 0.04 PPPY; P = 0.466) were similar before and after addition of Gla‐300. Conclusions: In US real‐world clinical practice, adding Gla‐300 to GLP‐1RA significantly improved glycaemic control without significantly increasing hypoglycaemia in PWD2. Further research into the effect of adding Gla‐300 to GLP‐1RA therapy is warranted. [ABSTRACT FROM AUTHOR]

In PWD2 inadequately controlled with GLP-1 RA therapy, addition of basal insulin is recommended. We used a US electronic medical record data source (IBM Explorys) of ~4 million PWD2 to assess the real-world impact of adding the basal insulin analog Gla-300 to GLP-1RA therapy in PWD2. Insulin-naïve PWD2 receiving GLP1-RAs who subsequently received Gla-300 between Mar 1, 2015-Sep 30, 2019 were identified; patients were required to have data for ≥12 months prior, and ≥6-month after, addition of Gla-300. Mean age of participants (N=271) was 57.9 (SD: 10.8) years. Baseline HbA1c was 9.16%, and was significantly reduced (0.97 [SD:1.60], p<0.0001) after addition of Gla-300; a significant increase in proportion of PWD2 achieving HbA1c control was observed after addition of Gla-300 (HbA1c <7.0%: 4.80% vs. 22.14%, p<0.0001; HbA1c <8.0%: 19.56% vs. 51.29%, p<0.0001). Incidence of overall (8.49% vs. 9.59%, p=0.513), and inpatient/emergency room-associated hypoglycemia (0.37% vs. 0.74%, p=1.000), as well as overall (0.33 vs. 0.46 PPPY, p=0.170) and inpatient/emergency room-associated hypoglycemia events (0.01 vs. 0.04 PPPY, p=0.466) were similar before and after addition of Gla-300. In US RW clinical practice, adding Gla-300 to GLP-1 RA significantly improved glycemic control without significantly increasing hypoglycemia. Disclosure: T. S. Bailey: Consultant; Self; Abbott Diabetes, LifeScan, Novo Nordisk, Sanofi, Research Support; Self; Abbott, Abbott Diabetes, Biolinq, Capillary Biomedical, Inc., Dexcom, Inc., Eli Lilly and Company, Kowa Research Institute, Inc., Lexicon Pharmaceuticals, Inc., Livongo, Medtronic, Medtrum Technologies, Novo Nordisk, REMD Biotherapeutics, Sanofi, Sanvita, Viacyte, Inc., vTv Therapeutics, Zealand Pharma A/S, Speaker's Bureau; Self; BD, Medtronic, Sanofi. J. Westerbacka: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. C. Nicholls: Employee; Self; Sanofi. J. Gill: Employee; Self; Sanofi US, Other Relationship; Self; American Diabetes Association, Stock/Shareholder; Self; Sanofi US. M. Jones s: None. L. Shenoy: None. Funding: Sanofi [ABSTRACT FROM AUTHOR]